Effect of an oral astaxanthin prodrug (CDX-085) on lipoprotein levels and progression of atherosclerosis in LDLR -/- and ApoE -/- mice

Atherosclerosis

Volumn 222, Issue 1, 2012, Pages 99-105

  Ryu, Sung Kee ^a,b   King, Timothy J ^c   Fujioka, Kazutoshi ^c   Pattison, Jennifer ^a   Pashkow, Fredrick J ^c   Tsimikas, Sotirios ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Eulji General Hospital   (South Korea)

^c Cardax Pharmaceuticals   (United States)

Author keywords

Antioxidants; Atherosclerosis; Carotenoids; Inflammation; Lipoproteins

Indexed keywords

APOLIPOPROTEIN E; ASTAXANTHIN; CDX 085; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; PRODRUG; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ARCH; AORTA ATHEROSCLEROSIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; DISEASE COURSE; DRUG DELIVERY SYSTEM; DRUG EFFECT; EXPERIMENTAL DOG; FAST PROTEIN LIQUID CHROMATOGRAPHY; FEMALE; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SINGLE DRUG DOSE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; AORTIC DISEASES; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CHOLESTEROL; DOGS; LIPOPROTEINS; MALE; MICE; MICE, KNOCKOUT; PRODRUGS; RECEPTORS, LDL; TRIGLYCERIDES; XANTHOPHYLLS;

EID: 84859870738     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.02.002     Document Type: Article

References (36)

1. Milani R.V., Lavie C.J. Another step forward in refining risk stratification: moving past low-density lipoprotein cholesterol. J Am Coll Cardiol 2011, 58:464-466.
2. Ridker P.M., Danielson E., Fonseca F.A., et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009, 373:1175-1182.
3. Dzau V.J., Antman E.M., Black H.R., et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: Part I: pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation 2006, 114:2850-2870.
4. Tsuruoka S., Kawaguchi A., Nishiki K., et al. Vitamin E-bonded hemodialyzer improves neutrophil function and oxidative stress in patients with end-stage renal failure. Am J Kidney Dis 2002, 39:127-133.
5. Inoue I., Takahashi K., Kikuchi C., et al. LDL apheresis reduces the susceptibility of LDL to in vitro oxidation in a diabetic patient with hemodialysis treatment. Diabetes Care 1996, 19:1103-1107.
6. Boaz M., Smetana S., Weinstein T., et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000, 356:1213-1218.
7. Rodrigo R., Guichard C., Charles R. Clinical pharmacology and therapeutic use of antioxidant vitamins. Fundam Clin Pharmacol 2007, 21:111-127.
8. Asleh R., Guetta J., Kalet-Litman S., et al. Haptoglobin genotype- and diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo. Circ Res 2005, 96:435-441.
9. Pashkow F.J., Watumull D.G., Campbell C.L. Astaxanthin: a novel potential treatment for oxidative stress and inflammation in cardiovascular disease. Am J Cardiol 2008, 101:58D-68D.
10. Jacobsson L.S., Yuan X.M., Zieden B., et al. Effects of alpha-tocopherol and astaxanthin on LDL oxidation and atherosclerosis in WHHL rabbits. Atherosclerosis 2004, 173:231-237.
11. Li W., Hellsten A., Jacobsson L.S., et al. Alpha-tocopherol and astaxanthin decrease macrophage infiltration, apoptosis and vulnerability in atheroma of hyperlipidaemic rabbits. J Mol Cell Cardiol 2004, 37:969-978.
12. Uchiyama A., Okada A. Clinical efficacy of astaxanthin-containing Haematococcus Pluvialis extract for the voluntees at risk of metabolic syndrome. J Clin Biochem Nutr 2008, 43:38-43.
13. Ikeuchi M., Koyama T., Takahashi J., et al. Effects of astaxanthin in obese mice fed a high-fat diet. Biosci Biotechnol Biochem 2007, 71:893-899.
14. Yoshida H., Yanai H., Ito K., et al. Administration of natural astaxanthin increases serum HDL-cholesterol and adiponectin in subjects with mild hyperlipidemia. Atherosclerosis 2010, 209:520-523.
15. Iwamoto T., Hosoda K., Hirano R., et al. Inhibition of low-density lipoprotein oxidation by astaxanthin. J Atheroscler Thromb 2000, 7:216-222.
16. Rishton G.M. Natural products as a robust source of new drugs and drug leads: past successes and present day issues. Am J Cardiol 2008, 101:43D-49D.
17. McNulty H.P., Byun J., Lockwood S.F., et al. Differential effects of carotenoids on lipid peroxidation due to membrane interactions: X-ray diffraction analysis. Biochem Biophys Acta 2007, 1768:167-174.
18. Lockwood S.F., Gross G.J. Disodium disuccinate astaxanthin (Cardax): antioxidant and antiinflammatory cardioprotection. Cardiovasc Drug Rev 2005, 23:199-216.
19. Lauver D.A., Driscoll E.M., Lucchesi B.R. Disodium disuccinate astaxanthin prevents carotid artery rethrombosis and ex vivo platelet activation. Pharmacology 2008, 82:67-73.
20. Khan S.K., Malinski T., Mason R.P., et al. Novel astaxanthin prodrug (CDX-085) attenuates thrombosis in a mouse model. Thromb Res 2010, 126:299-305.
21. Sanz J., Moreno P.R., Fuster V. The year in atherothrombosis. J Am Coll Cardiol 2010, 55:1487-1498.
22. Davignon J., Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004, 109:III27-III32.
23. Hartvigsen K., Binder C.J., Hansen L.F., et al. A diet-induced hypercholesterolemic murine model to study atherogenesis without obesity and metabolic syndrome. Arterioscler Thromb Vasc Biol 2007, 27:878-885.
24. Tangirala R.K., Casanada F., Miller E., et al. Effect of the antioxidant N,N'-diphenyl 1,4-phenylenediamine (DPPD) on atherosclerosis in apoE-deficient mice. Arterioscler Thromb Vasc Biol 1995, 15:1625-1630.
25. Tsimikas S., Shortal B.P., Witztum J.L., et al. In vivo uptake of radiolabeled MDA2, an oxidation-specific monoclonal antibody, provides an accurate measure of atherosclerotic lesions rich in oxidized LDL and is highly sensitive to their regression. Arterioscler Thromb Vasc Biol 2000, 20:689-697.
26. Torzewski M., Shaw P.X., Han K.R., et al. Reduced in vivo aortic uptake of radiolabeled oxidation-specific antibodies reflects changes in plaque composition consistent with plaque stabilization. Arterioscler Thromb Vasc Biol 2004, 24:2307-2312.
27. Witztum J.L., Steinberg D. The oxidative modification hypothesis of atherosclerosis: does it hold for humans?. Trends Cardiovasc Med 2001, 11:93-102.
28. Steinberg D., Witztum J.L. Oxidized low-density lipoprotein and atherosclerosis. Arterioscler Thromb Vasc Biol 2010, 30:2311-2316.
29. Steinberg D. Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: Part I. J Lipid Res 2004, 45:1583-1593.
30. Heinecke J.W. Oxidative stress: new approaches to diagnosis and prognosis in atherosclerosis. Am J Cardiol 2003, 91:12A-16A.
31. Sugamura K., Keaney J.F. Reactive oxygen species in cardiovascular disease. Free Rad Res Comm 2011, 51:978-992.
32. Pashkow F.J. Oxidative stress and inflammation in heart disease: do antioxidants have a role in treatment and/or prevention?. Int J Inflam 2011, 2011:514623.
33. During A., Dawson H.D., Harrison E.H. Carotenoid transport is decreased and expression of the lipid transporters SR-BI, NPC1L1, and ABCA1 is downregulated in Caco-2 cells treated with ezetimibe. J Nutr 2005, 135:2305-2312.
34. Yang Y., Seo J.M., Nguyen A., et al. Astaxanthin-rich extract from the green alga Haematococcus pluvialis lowers plasma lipid concentrations and enhances antioxidant defense in apolipoprotein E knockout mice. J Nutr 2011, 141:1611-1617.
35. Hussein G., Nakagawa T., Goto H., et al. Astaxanthin ameliorates features of metabolic syndrome in SHR/NDmcr-cp. Life Sci 2007, 80:522-529.
36. Qiao L., Zou C., van der Westhuyzen D.R., et al. Adiponectin reduces plasma triglyceride by increasing VLDL triglyceride catabolism. Diabetes 2008, 57:1824-1833.